Cholesterol

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

Young, non-diabetic individuals were most likely to delay statin initiation for low-density lipoprotein cholesterol (LDL-C) lowering, increasing their risk of myocardial infarction.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

A series of PCSK9 inhibitors were found to be tolerable and effective at reducing low-density lipoprotein cholesterol in solid organ transplant recipients.

Recaticimab significantly lowered low-density lipoprotein cholesterol (LDL-C) levels, showing promise in becoming a future proprotein convertase subtilisin/kexin type 9 (PCSK9) option for cholesterol reduction.

In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.

A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.

A retrospective analysis found widespread lack of low-density lipoprotein cholesterol (LDL-C) goal attainment, posing risks for those at very high cardiovascular risk.

Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms to lower their low-density lipoprotein cholesterol (LDL-C).

A systematic review and meta-analysis revealed key insights into lipid parameters in patients with systemic sclerosis.

High-density lipoprotein cholesterol, known for protective cardiovascular effects, could play a role in reducing the risk of stress urinary incontinence.

By improving low-density lipoprotein cholesterol (LDL-C) levels, statins reduced complications after pipeline embolization device implantation for intracranial aneurysms.

Multiple FDA-approved drugs without lipid-lowering indications were identified to have potential lipid-lowering properties.

Inclisiran was found to have a lower risk of new-onset diabetes compared with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies.

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

Kirk Knowlton, MD, discusses findings from the V-INCEPTION trial evaluating inclisiran for low-density lipoprotein cholesterol (LDL-C) management after myocardial infarction, highlighting its real-world effectiveness, tolerability, and potential for integration into pharmacist-led lipid care pathways.

Patients with ASCVD face increased cardiovascular risks post revascularization, yet many miss timely LDL-C testing and treatment, highlighting critical care gaps.

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).

Researchers unveil a groundbreaking method using polypurine hairpins to inhibit PCSK9, offering a promising alternative for lowering cholesterol and reducing cardiovascular risk.

Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.

By closing the gap on patients who are recommended lipid-lowering therapies but do not receive them, researchers say that thousands of cardiovascular events could be prevented and billions of dollars would be saved.

Although cholesterol-lowering guidance often touts the achievement of very low levels of low-density lipoprotein (LDL) cholesterol, emerging research demonstrates possible safety risks.

Stroke, myocardial infarction, and all-cause death were included in the composite of adverse cardiovascular events.

HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, whereas NPC1L1 inhibitors were found to reduce the risk.

Remnant cholesterol, a novel lipoprotein marker linked to elevated triglycerides, is associated with increased risk of progression and development of chronic kidney disease.